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Abstract: We performed high-throughput cDNA sequencing in colorectal adenocarcinoma and matching normal 
colorectal epithelium. All six hundred three genes in the UCSC database that were expressed in colon cancers and 
contained open reading frames of 1000 nucleotides or less were selected for study (total basepairs/bp, 366,686). 
304,350 of these 366,686 bp (83.0%) were amplified and sequenced successfully. Seventy-eight sequence variants 
present in germline (i.e. normal) as well as matching somatic (i.e. tumor) DNA were discovered, yielding a fre-
quency of 1 variant per 3,902 bp. Fifty-one of these sequence variants were homozygous (26 synonymous, 25 non-
synonymous), while 27 were heterozygous (11 synonymous, 16 non-synonymous). Cancer tissue contained only one 
sequence-altered allele of the gene ATP50, which was present heterozygously alongside the wild-type allele in match-
ing normal epithelium. Despite this relatively large number of bp and genes sequenced, no somatic mutations unique 
to tumor were found. High-throughput cDNA sequencing is a practical approach for detecting novel sequence 
variations and alterations in human tumors, such as those of the colon.
Introduction
It is widely believed that somatic as well as germline mutations play important roles in the origin 
and progression of colorectal cancers (Calvert and Frucht, 2002). Many genes have been inves-
tigated for mutation to elucidate mechanisms of colorectal cancer development, with these inves-
tigations demonstrating the involvement of mutations in colorectal carcinogenesis and progression. 
Samuels et al. reported that PIK3CA, a catalytic subunit of the class IA phosphatidylinositol 3-
kinases, was somatically mutated in 32% of colorectal cancers, resulting in the attenuation of 
apoptosis and facilitated tumor invasion(Samuels et al. 2004). A comprehensive study entitled, 
“The Tyrosine Phosphatome” was accomplished by sequencing all genes involved in tyrosine 
phosphorylation in a large cancer cohort consisting of 175 colorectal cancer patients(Wang et al. 
2004). Most mutational studies, however, have been preoccupied with the prevalence of somatic 
mutations in a specific single candidate gene in relatively small colorectal cancer patient cohorts. 
Recently, Sjoblom et al. reported the genome-wide frequencies of somatically mutated genes in 
human breast and colorectal cancers(Sjoblom et al. 2006). However, the methods these used were 
extremely expensive, time-consuming, and labor-intensive for a typical laboratory to perform. 
More practical strategies, amenable to smaller laboratories with more conservative budgets, would 
be of great value in the continuing quest to answer questions in the fields of tumor genomics and 
mutatomics. To this end, we present herein a circumscribed, practical mutational study employing 
high-throughput cDNA sequencing in colon adenocarcinoma, in which we demonstrate the eminent 
feasibility and results of determining sequence variation efficiently and at low cost.
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Materials and Methods
Tissue samples
Colorectal cancer and its matching normal colonic 
mucosa from a patient undergoing surgical resec-
tion at the Baltimore VA Hospital after signing 
informed research consent was used for this study. 
Clinicopathological data were as follows: 75 year-
old male; moderately-differentiated colorectal 
adenocarcinoma of the ascending colon; tumor 
size, 2.5 × 1.1 × 0.5 cm; TNM stage (Fifth Edition 
of the TNM classiﬁ  cation of the UICC, 1997), 
T2N0MX, without any other malignancies. Both 
colorectal adenocarcinoma and normal colonic 
epithelium (obtained at the location within the 
surgically resected specimen furthest from the 
tumor) were cut into smaller pieces and frozen in 
liquid nitrogen immediately after removal. A 
frozen aliquot of each specimen was crushed into 
pieces and lysed immediately in either TRIZOL 
reagent (Invitrogen Corp., Carlsbad, CA,) to 
extract total RNA, or lysis buffer of a DNeasy 
Tissue kit (QIAGEN Inc., Valencia, CA) to extract 
DNA, according to these manufacturers’ instruc-
tions.
Cell lines
HeLa S3, HT29, HCT15, HCT116, LoVo, CaCo2, 
LS174T, LS411N, and DLD1, purchased from the 
American Type Culture Collection (ATCC), and 
KYSE30, 70, 110, 150, 220, 410, 770, 850 and 
OE33, obtained from Dr. Yutaka Shimada at Kyoto 
University in Japan (Shimada et al. 1992), were 
enrolled in the current study in order to validate 
our ﬁ  ndings in the ATP50 gene. Culture conditions 
for each cell line were according to ATCC and the 
establisher’s recommendations. All cell lines were 
supplemented with 10% fetal bovine serum plus 
an appropriate concentration of penicillin and 
streptomycin.
Gene selection
To increase our chances of successfully amplifying 
and sequencing cDNAs, we restricted our study to 
genes that are known to be expressed in colorectal 
cancer cells, based on a gene expression database 
at the University of California, Santa Cruz (UCSC) 
[http://genome.ucsc.edu/index.html]. From among 
this gene set, we selected a subset of genes 
(approximately 600) containing open reading 
frames (ORFs) 1000 nucleotides or shorter in 
length. To automate design of the large number of 
primer sets required, we developed an in-house 
primer design algorithm based on the publicly 
available primer design software program, Primer3 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www_slow.cgi). PCR products were designed to 
range from 300 to 500 bp in length. ORFs of 
cDNAs longer than 500 bp were divided into 2 or 
3 fragments; primers were then designed with 
adjacent fragments overlapped, in order to 
completely cover these longer ORFs. Finally, for 
each heterozygous sequence alteration, genomic 
DNA primers (available on request) were designed 
to conﬁ  rm cDNA sequencing results.
RT-PCR
Total RNA extracted from colorectal adenocarci-
noma and normal colonic epithelium was reverse-
transcribed using a SuperScript III First-Strand kit 
(Invitrogen, Carlsbad, CA), and respective cDNA 
pools were made. RT-PCR was performed using 
an AccuPrime Supermix I Kit (Invitrogen). The 
PCR protocol was as follows: 1 min at 96 °C 
followed by 35 cycles of 30 sec at 94 °C, 45 sec 
at 58 °C, and 1 min at 72 °C. Secondary PCR was 
performed on puriﬁ  ed template from the ﬁ  rst RT-
PCR product, using the same protocol.
Sequencing
A BigDye Terminator v3.1 Kit (Applied Biosys-
tems, Foster City, CA) was used for the 
sequencing reaction, and sequence products 
were read on an SCE 9610 automated 96-capil-
lary sequencer (Spectruby BaseSpectrum v2.10 
(SpectruMedix) and analyzed with Mutation 
Surveyor v2.2 (SoftGenetics LLC, State 
College, PA). Each time candidate sequence 
alterations were discovered in cDNA from 
colorectal cancer tissue, identical procedures 
were followed in matched normal epitheliam to 
confirm whether or not they represented somatic 
alterations. After candidate alterations were 
confirmed, the entire procedure was repeated 
separately on a fresh aliquot of cDNA from both 
the cancer and normal specimens in order to 
exclude amplification or technical errors due to 
two-stage PCR. Genomic DNA sequencing was 
also performed on heterozygous sequence vari-
ants to confirm that identical sequence altera-
tions were present in genomic DNA.3
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Methylation-speciﬁ  c PCR (MSP)
Because the gene ATP50 was apparently mutated, 
raising the possibility that it was a tumor suppressor 
gene, we evaluated this gene for alternative inac-
tivation via promoter hypermethylation. MSP 
primer sequences of ATP50 for the methylated 
reaction were: forward (5′-CGAGTGGGAGC-
GATTTAGGAC-3′) and reverse (5′-AACGC-
CAAAATTACGACACG-3′), which amplify a 
94-bp product. Β-actin was selected as an internal 
control gene, using previously published MSP 
primers (Eads et al. 2001). CpGenome Universal 
Methylated DNA (Chemicon International, Inc., 
Temecula, CA) was used as a positive control. The 
detailed MSP procedure has been previously 
published (Sato et al. 2002).
Microsatellite instability (MSI) assay
MSI at each locus was determined by analyses of 
the length of each PCR-ampliﬁ  ed microsatellite. 
MSI status was conﬁ  rmed by MSI assays at ﬁ  ve 
consensus loci (BAT25, BAT26, D2S123, D5S346, 
and D17S250) according to criteria from a National 
Cancer Institute workshop (Boland et al. 1998). 
Detailed procedures were as previously described 
(Mori et al. 2001).
Results
Project overview 
A total of 603 genes (S-Table 1) were selected 
based on their length (under 1,000 bp) and their 
predicted expression in colorectal cancers according 
to the UCSC database. One thousand thirty-eight 
primer pairs (available on request) were designed 
to cover the entire ORFs (total bp, 366,687) of 
these 603 genes. Sequence data from 862 (83.0%) 
of these 1,038 primer sets were successfully 
analyzed, meaning that approximately 304,350 
total bp were successfully sequenced (all primer 
sets for RT-PCR and cDNA sequencing are avail-
able on request).
Sequence variants
Seventy-eight sequence variants within 50 genes 
were found among the 603 genes studied (Table 1) 
(S-Table 2 for detailed information). Thus, the 
frequency of sequence variants was 1 per 3,902 
bp (78 total variants/304,350 total bp). Of these 
78 sequence alterations, 51 were homozygous 
(26 synonymous, 25 non-synonymous) and 27 
were heterozygous (11 synonymous, 16 
Figure 1. cDNA sequencing of ATP50. Two different alteration sites were detected. At the 108th nucleotide, colorectal cancer tissue had 
only a mutant cytosine nucleotide, while normal colon contained both a thymine (wild) and a cytosine (mutant). Both codons GGT and GGC 
encoded glycine (synonymous alteration). At the 218th mucleotide, colorectal cancer tissue had only a mutant guanine nucleotide, while 
normal tissue contained both an adenine (wild) and a guanine (mutant). AAA encoded lysine and AGA encoded arginine (non-synonymous 
alteration). Gly, glycine; Arg, arginine.4
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non-synonymous). All sequence alterations were 
detected in both colorectal cancer tissue and 
matched normal colonic epithelium, with the 
exception of an alteration in the gene ATP50 
(NM_001697), which manifested a unique 
expression mechanism (Fig. 1). Forty-four 
sequence alterations had been previously 
reported, but 34 sequence alterations were 
completely novel, having never been reported in 
the SNP database at The National Center for 
Biotechnology Information (NCBI).
Tumor-speciﬁ  c regulation of gene 
expression
Tumor-speciﬁ  c regulation of gene expression was 
found for NM_001697 (ATP50, Homo sapiens 
ATP synthase, H+ transporting, mitochondrial 
F1 complex, O subunit). The sequence alterations 
T108C (GGT to GGC, homozygous, Gly36Gly) 
and A218G (AAA to AAG, homozygous, 
Lys73Arg) were observed only in cancer-derived 
cDNA, while the alterations T108TC (CGT and 
GGC, heterozygous, 36Gly) and A218AG (AAA 
and AAG, heterozygous, 73Lys and 73 Arg) were 
observed in cDNA from normal epithelium. 
Surprisingly, both T108TC (CGT and GGC, 
heterozygous, 36Gly) and A218AG (AAA and 
AAG, heterozygous, 73Lys and 73 Arg), which 
were identical to the two alterations observed in 
normal cDNA, were observed in genomic DNA 
from both cancer and normal tissue (Figures 2, 3). 
This result implied that the cancer exhibited 
monoallelic expression from the variant allele of 
ATP50, while the normal epithelium manifested 
biallelic heterozygous expression, i.e. from both 
the reported normal allele and our discovered 
variant mutant allele simultaneously.
MSP
One possible mechanism for monoallelic expres-
sion observed for ATP50 was DNA methylation of 
its promoter region. MSP showed, however, that 
there was no methylation of the ATP50 promoter 
in colorectal cancer (S-Fig. 1).
Somatic mutations
There were no somatic mutations found among the 
603 genes studied or within the p53 gene.
MSI status
MSI assays showed that there was no microsatellite 
instability in genomic DNA (S-Fig. 2).
Discussion
In the current study, we assumed that if a mutant 
protein was involved in carcinogenesis or tumor 
progression, this mutant would be expressed and 
therefore detectable in tumor mRNA. i.e. we 
assumed that somatic mutations involved in 
carcinogenesis or tumor progression would be 
detectable by direct cDNA sequencing. By using 
this strategy, we avoided the need for sequencing 
each exon of genomic DNA, reasoning that genes 
which are never expressed in normal or malignant 
colon probably do not participate in colorectal 
carcinogenesis. We discovered 78 sequence vari-
ants (44 of which had been previously reported as 
single-nucleotide polymorphisms, but 34 of which 
had never been reported) among the 603 genes 
(304,350 bp of ORFs) studied.
Recently, Sjoblom T. et al. performed genome-
wide sequencing in breast and colorectal cancers, 
revealing that an average of 52 mutations occurred 
in each colorectal cancer(Sjoblom et al. 2006). 
According to the article by Sjoblom et al. the 
somatic mutation frequency in colon cancers was 
3.2 somatic mutations/Mb, on average (Table 1 of 
their paper). Therefore, the probability of our 
ﬁ  nding zero somatic mutations among the 603 
genes (304,350 bp) that we studied was 37.76% 
(please see formula below), suggesting that our 
ﬁ  ndings were statistically quite consistent with 
Sjoblom’s results:
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Table 1. Sequence variants
 Homozygous  Heterozygous
 Synonymous  Non-synonymous  Synonymous  Non-synonymous
Number of alterations  26  25  11  165
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The Sjoblom team also deﬁ  ned “CAN-genes” 
(candidate cancer genes) as those that were 
frequently mutated in colorectal cancers, and found 
that 69 genes could be included in this category. 
Although the CAN-genes KRAS, GNAS and TP53 
were studied by us, no somatic mutations were found 
in these genes. Furthermore, in addition to the genes 
mentioned above, NRAS, HRAS, p16, and p27 were 
included in the current study, but these genes also 
contained no somatic mutations. Finally, results of 
MSI assays revealed MS-stability (MSS), implying 
an absence of mutations in the major DNA mismatch 
repair genes (although these genes were not studied 
due to their long ORFs). It is possible that other 
molecular pathogenetic pathways were involved in 
this colorectal tumorigenesis, such as those 
containing APC, MCC, DCC, or the TGF-β cascade: 
these genes were also not examined in the current 
study due to ORF length.
Approximately 24,000,000 bp among the entire 
genomic DNA sequence are reported as ORFs in 
the UCSC database. The average density of each 
SNP is once per 1.9 kilobases (i.e. 1,419,190 
SNPs/2.7 gigabases of human genome 
sequence)(Sachidanandam et al. 2001). We 
sequenced 304,350 bp of ORFs (viz., 1.26% of the 
total ORFs in the UCSC database: 304,350 
bp/24,000,000 bp) and discovered 78 sequence 
variants, yielding a frequency of 1 alteration per 
3,902 bp (78/304,350 bp). Our observed sequence 
variant distribution may provide a basis with which 
to estimate the number of SNPs in a single indi-
vidual with colon cancer. That is, the SNPs reported 
above are one possible subset of the entire database; 
there is no guarantee that a given individual will 
always harbor all SNPs in the database.
The human ATP50 gene (X83218, NM_
001697), encoding a 213-amino acid ATP synthase 
OSCP subunit, is a key structural component of 
the stalk of the mitochondrial respiratory chain 
F1F0-ATP synthase, which is a vital element in the 
cellular pathway of energy conversion (Senior, 
Figure 2. Representative result of cDNA sequencing of ATP50 in normal and cancer tissues. The red box in the left panel shows the 36th 
codon, while the red box in the right panel shows the 73rd codon. All alterations were conﬁ  rmed by both forward and reverse sequencing.6
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1988). Although a mutant strain of yeast in which 
the delta subunit of F1F0-ATP synthase had been 
inactivated by insertional mutagenesis showed 
little or no ATPase activity(Giraud and Velours, 
1994), and dysfunction of ATP synthase can cause 
a variety of degenerative diseases(Wallace, 1994), 
there have been no previous reports detailing a 
relationship between ATP synthase and tumorigen-
esis. We found restricted monoallelic (i.e. monoal-
lelically silenced) expression of an altered allele 
from ATP50 in our colon cancer tissue, which 
would be expected to exert the same effect as 
would a somatic mutation of this gene. Genomic 
DNA sequencing of ATP50 revealed that this 
monoallelic expression was not due to LOH. We 
therefore studied the methylation status of the CpG 
island in the promoter region of ATP50 by MSP, 
but we found no methylation of this region. Other 
epigenetic mechanisms, such as histone deacety-
lation, might have contributed to monoallelic 
expression of ATP50. There was no monoallelic 
expression of ATP50 in 20 cancer cell lines that 
we examined. Although monoallelic expression of 
this altered ATP50 allele may be involved in a 
subset of colorectal cancers, further study is 
required to clarify the potential functional role of 
this gene in carcinogenesis.
This study poses several advantages as well 
as limitations. Firstly, it has been reported that 
some synonymous mutations may influence the 
stability of mRNA(Duan and Antezana, 2003; 
Chamary and Hurst, 2005) because they affect 
the thermodynamic stability of mRNA secondary 
structures (Fitch, 1974; Klambt, 1975). Nonsense-
mediated mRNA decay (NMD) is also known as 
a surveillance pathway that rapidly degrades 
mRNAs containing premature termination 
codons(Culbertson and Leeds, 2003; Amrani 
et al. 2006). These mechanisms may cause 
instability of mRNA, accelerate the degradation 
of mRNA, and consequently result in difficulty 
in detecting sequence alterations by cDNA 
sequencing. Since we used cDNA as our starting 
material for sequencing, we may have ignored 
some key genes because of RNA degradation. 
Nevertheless, many sequence variants were 
detected reasonably well in the current study, 
suggesting that degradation of mRNA occurred 
rarely, if at all, as a consequence of sequence 
alterations. Instead, we considered it more 
important to increase our chances of finding 
sequence alterations by using cDNA rather than 
genomic DNA because of the lower cost, time, 
and labor involved in sequencing cDNA, as well 
Figure 3. Genomic DNA sequencing of ATP50 in normal and cancer tissues. Upper panels, forward sequencing; lower panels, reverse 
sequencing. The red boxes show the 36th and 73rd codons. Both normal and colorectal cancer tissues contain identical heterozygosities at 
the 108th and 218th nucleotides.7
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as the increased relevance of only studying 
genes that are expressed in the colon.
Secondly, it is conceivable that we lost some 
gene sequence information due to extremely low 
expression levels. Therefore, we employed two-
stage PCR to increase our chances of successful 
sequencing, thereby achieving a relatively high 
success rate of 862/1,038 reactions, or 83.0%. 
Possibly, this result still may have included genes 
that were not expressed in our particular colorectal 
cancer, even though we used the UCSC database 
to select genes that were purportedly expressed in 
colorectal cancers. Our sequencing success rate 
appears favorable when compared to genomic 
DNA sequencing, where 92% of genes were 
successfully analyzed (Wang et al. 2004). The total 
number of exons sequenced in our study was 2107, 
implying that at least 2107 primer pairs would have 
been necessary to conduct this study had it been 
attempted by genomic DNA sequencing; in 
contrast, we accomplished this task using only 
1038 primer sets for cDNA sequencing. This 
contrast demonstrates that our method is useful to 
explore mutations because it is not only more cost-
effective, but also less demanding in time and 
labor.
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Supplement Material
S-Figure 2. A representative result of MSI typing. Both cancer and normal tissue showed microsatellite stable in the marker of D5S346 and 
D17S250. The similar results were obtained in the marker of D2S123, BAT25, and BAT26.
S-Figure 1. Result of MSP for ATP50. (A) Bisulﬁ  ted DNA from cancer tissue, normal tissue, and HT29 were used. The MSPs for ATP50 
were triplicated. The MSP product for ATP50 was 94 bp and beta actin was 133bp. (B) Universal methylated DNA was used for the positive 
control in various amounts. M.W., molecular weight.9
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S-Table-1. Gene list
GenBank   Gene   GenBank   Gene   GenBank   Gene 
Accession No.   Symbol   Accession No.   Symbol   Accession No.   Symbol 
NM_000100.2 CSTB    NM_198057.1 TSC22D3    NM_002811.3  PSMD7 
NM_000999.2 RPL38    NM_022652.2 DUSP6    NM_002812.3  PSMD8 
NM_001827.1 CKS2    NM_021121.2 EEF1B2    NM_002813.4  PSMD9 
NM_001863.3 COX6B1    NM_001412.2 EIF1AX    NM_170750.1  PSMD10 
NM_001866.2 COX7B    NM_004094.3 EIF2S1    NM_004577.3  PSPH 
NM_001867.2 COX7C    NM_001423.1 EMP1    NM_175847.1  PTBP1 
NM_002489.2 NDUFA4    NM_001424.3 EMP2    NM_198974.1  PTK9 
NM_002491.1 NDUFB3    NM_001425.1 EMP3    NM_002823.2   PTMA 
NM_002966.1 S100A10    NM_207168.1 ENSA   NM_002824.4   PTMS 
NM_003009.2 SEPW1    NM_001005915.1 ERBB3    NM_133377.1   RAD1 
NM_003063.1 SLN    NM_001983.2 ERCC1    NM_153824.1   PYCR1 
NM_003095.1 SNRPF    NM_001984.1 ESD    NM_000320.1   QDPR 
NM_003133.1 SRP9    NM_001439.1 EXTL2    NM_004161.3   RAB1A 
NM_003498.3 SNN    NM_001997.2 FAU    NM_004162.3   RAB5A 
NM_003746.1 DYNLL1    NM_005247.2 FGF3   NM_002868.2   RAB5B 
NM_003860.2 BANF1    NM_002007.1 FGF4   NM_198896.1   RAB6A 
NM_003945.3 ATP6V0E    NM_002010.1 FGF9   NM_002870.2   RAB13 
NM_004045.2 ATOX1    NM_023108.1 FGFR1    NM_183235.1   RAB27A 
NM_004485.2 GNG4    NM_001449.3 FHL1   NM_201434.1  RAB5C 
NM_004541.2 NDUFA1    NM_054014.1 FKBP1A    NM_198829.1  RAC1 
NM_004772.1 C5orf13    NM_002013.2 FKBP3    NM_002872.3  RAC2 
NM_005274.1 GNG5    NM_016725.1 FOLR1    NM_133630.1  RAD51L3 
NM_005517.2 HMGN2    NM_004477.1 FRG1   NM_002881.2  RALB 
NM_005694.1 COX17    NM_000146.2 FTL    NM_006325.2  RAN 
NM_005770.3 SERF2    NM_198903.1 GABRG2    NM_002884.1  RAP1A 
NM_005887.1 DLEU1    NM_000166.2 GJB1   NM_015646.3  RAP1B 
NM_005949.1 MT1F    NM_024009.2 GJB3   NM_032626.5  RBBP6 
NM_005954.2 MT3    NM_002061.2 GCLM    NM_181558.1  RFC3 
NM_005978.3 S100A2    NM_006708.1 GLO1   NM_181578.1  RFC5 
NM_006156.1 NEDD8    NM_002066.1 GML    NM_134427.1  RGS3 
NM_006274.2 CCL19    NM_016592.1 GNAS    NM_005614.2  RHEB 
NM_006304.1 SHFM1    NM_005301.2 GPR35    NM_000326.3  RLBP1 
NM_006353.2 HMGN4    NM_002083.2 GPX2   NM_002938.2  RNF4 
NM_006698.2 BLCAP    NM_002084.2 GPX3   NM_183045.1  RNF6 
NM_006829.2 C10orf116   NM_203506.1 GRB2    NM_002946.3  RPA2 
NM_007233.1 TP53AP1    NM_001512.2 GSTA4    NM_002947.3  RPA3 
NM_007281.1 SCRG1    NM_147149.1 GSTM4    NM_033301.1  RPL8 
NM_012456.1 TIMM10    NM_145871.1 GSTZ1    NM_033251.1  RPL13 
NM_012458.2 TIMM13    NM_004492.1 GTF2A2    NM_000985.2  RPL17 
NM_012460.2 TIMM9    NM_002095.3 GTF2E2    NM_000984.3  RPL23A 
NM_013332.1 HIG2    NM_000858.3 GUK1    NM_000992.2  RPL29 
NM_013343.1 LOH3CR2A    NM_005318.2 H1F0   NM_001001.3  RPL36AL 
NM_014041.1 SPCS1    NM_002106.3 H2AFZ    NM_021029.3  RPL36A 
NM_014051.2 TMEM14A   NM_005324.3 H3F3B    NM_001002.3  RPLP0 
NM_014221.1 MTCP1    NM_005326.3 HAGH    NM_002949.2  MRPL12 
NM_014356.2 C6orf123    NM_005327.1 HADHSC    NM_001007.3  RPS4X 
NM_014445.2 SERP1    NM_005330.3 HBE1   NM_001015.3  RPS11 
NM_014624.3 S100A6    NM_004494.1 HDGF    NM_001019.3  RPS15A 
NM_014792.2 KIAA0125   NM_139011.1 HFE    NM_001020.3  RPS16 
NM_016096.2 ZNF706    NM_005340.3 HINT1    NM_001022.3  RPS19 
NM_016305.1 SS18L2    NM_002118.3 HLA-DMB    NM_001023.2  RPS20 
NM_016565.2 CHCHD8    NM_002128.3 HMGB1    NM_001025.3  RPS23 
NM_020142.3 LOC56901    NM_002129.2 HMGB2    NM_002960.1  S100A3 
NM_020179.1 FN5    NM_004965.6 HMGN1    NM_005620.1  S100A11 
NM_020181.1 C14orf162   NM_002131.2 HMGA1    NM_000664.3  ACACA 
NM_020248.1 CTNNBIP1    NM_173158.1 NR4A1    NM_198970.1  AES 
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S-Table-1. (Continued)
GenBank   Gene   GenBank   Gene   GenBank   Gene 
Accession No.   Symbol   Accession No.   Symbol   Accession No.   Symbol 
NM_020408.3  C6orf149    NM_002136.1  HNRPA1    NM_001636.1  SLC25A6 
NM_021104.1  RPL41    NM_031314.1  HNRPC    NM_001001787.1  ATP1B1 
NM_021127.1  PMAIP1   NM_002138.3  HNRPD    NM_001687.4  ATP5D 
NM_021177.3  LSM2    NM_021644.2  HNRPH3    NM_001002256.1   ATP5G3 
NM_023937.2  MRPL34    NM_006896.2  HOXA7    NM_004047.2  ATP6V0B 
NM_031286.2  SH3BGRL3    NM_153715.1  HOXA10    NM_198589.1  BSG 
NM_031287.2  SF3B5    NM_156037.1  HOXB6    NM_004927.2  MRPL49 
NM_032412.2  ORF1-FL49    NM_004502.2  HOXB7    NM_006136.2  CAPZA2 
NM_032574.1  LOC84661    NM_024016.2  HOXB8    NM_022845.2  CBFB 
NM_032747.1  USMG5   NM_014620.2  HOXC4    NM_001760.2  CCND3 
NM_052871.2  MGC4677    NM_153693.1  HOXC6    NM_171827.1  p32/CD8A 
NM_052971.1  LEAP-2    NM_006897.1  HOXC9    NM_001773.1  CD34 
NM_080677.1  DYNLL2   NM_014212.2  HOXC11    NM_000611.4  CD59 
NM_138448.2  ACYP2    NM_024501.1   HOXD1   NM_001780.3  CD63 
NM_139286.3  CDC26    NM_134421.1   HPCAL1   NM_004359.1  CDC34 
NM_194327.1  GALIG    NM_182638.1  HPS1    NM_058197.2  p16/CDKN2A 
NM_198835.1  ACACA    NM_005524.2  HES1    NM_001280.1  CIRBP 
NM_020115.3  ACRV1    NM_198431.1  HSPA4    NM_001833.1  CLTA 
NM_001124.1  ADM    NM_001540.2  HSPB1    NM_022645.2  CSH2 
NM_000674.1  ADORA1    NM_005528.1  DNAJC4    NM_012140.3  SLC25A10 
NM_000676.2  ADORA2B    NM_181353.1  ID1    NM_148979.1  CTSH 
NM_001630.1  ANXA8    NM_002166.4  ID2    NM_000396.2  CTSK 
NM_001154.2  ANXA5    NM_174856.1  IDH3B   NM_001336.2  CTSZ 
NM_080649.1  APEX1    NM_004508.2  IDI1    NM_001915.2  CYB561 
NM_000041.2  APOE    NM_005533.2  IFI35    NM_004418.2  DUSP2 
NM_152876.1  FAS    NM_021068.1  IFNA4   NM_004427.2  PHC2 
NM_000486.3  AQP2    NM_000612.2  IGF2    NM_001970.3  EIF5A 
NM_053286.1  AQP6    NM_001552.1  IGFBP4    NM_001419.2  ELAVL1 
NM_001659.1  ARF3    NM_000576.2  IL1B    NM_198194.1  STOM 
NM_001660.2  ARF4    NM_172200.1  IL15RA    NM_202001.1  ERCC1 
NM_001663.2  ARF6    NM_005536.2  IMPA1   NM_023110.1  FGFR1 
NM_001664.2  RHOA    NM_014214.1  IMPA2   NM_201557.1  FHL2 
NM_004040.2  RHOB    NM_198219.1  ING1    NM_004468.3  FHL3 
NM_175744.3  RHOC    NM_198337.1  INSIG1    NM_057092.1  FKBP2 
NM_005168.2  RND3    NM_002198.1  IRF1    NM_016730.1  FOLR1 
NM_001665.2   rho G   NM_004030.1  IRF7    NM_004477.1  FRG1 
NM_004309.3  ARHGDIA    NM_181493.1  ITPA    NM_002032.1   FTH1 
NM_001177.3  ARL1    NM_002228.3  JUN    NM_002035.1   FVT1 
NM_004311.2  ARL3    NM_002231.2  CD82    NM_001487.1   BLOC1S1 
NM_004314.1  ART1    NM_004137.2  KCNMB1    NM_004483.3  GCSH 
NM_032468.2  ASPH    NM_033360.2  KRAS   NM_004124.2  GMFB 
NM_005171.2  ATF1    NM_002295.2  RPSA    NM_000581.2  GPX1 
NM_004024.2  ATF3    NM_005563.3  STMN1    NM_002085.1  GPX4 
NM_001677.3  ATP1B1   NM_005564.2  LCN2    NM_147148.1  GSTM4 
NM_001679.2  ATP1B3   NM_005566.1  LDHA    NM_002095.3  GTF2E2 
NM_001001977.1  ATP5E    NM_201544.1  LGALS8    NM_002107.3  H3F3A 
NM_001002015.1  ATP5F1    NM_004987.3  LIMS1   NM_005342.1  HMGB3 
NM_005175.2  ATP5G1   NM_005574.2  LMO2   NM_002133.1  HMOX1 
NM_001002258.1  ATP5G3    NM_002346.1  LY6E    NM_002134.2  HMOX2 
NM_001003701.1  ATP5J    NM_002353.1  TACSTD2    NM_156036.1  HOXB6 
NM_001694.2  ATP6V0C    NM_014220.1  TM4SF1    NM_024017.3   HOXB9 
NM_001697.2  ATP5O    NM_002354.1  TACSTD1    NM_000194.1   HPRT1 
NM_004322.2  BAD    NM_030885.2  MAP4   NM_005343.2   HRAS 
NM_053056.1  CCND1    NM_203378.1  MB    NM_174856.1  IDH3B 
NM_138578.1  BCL2L1   NM_002386.2  MC1R   NM_000628.3  IL10RB 
NM_004050.2  BCL2L2   NM_182763.1  MCL1    NM_181431.1  FOXK2 
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S-Table-1. (Continued)
GenBank   Gene   GenBank   Gene   GenBank   Gene 
Accession No.   Symbol   Accession No.   Symbol   Accession No.   Symbol 
NM_000713.1  BLVRB    NM_012328.1  DNAJB9    NM_181468.1  ITGB4BP 
NM_005180.5  PCGF4   NM_005370.4  RAB8A    NM_201543.1  LGALS8 
NM_004331.2  BNIP3L   NM_177524.1  MEST    NM_002359.2  MAFG 
NM_032515.3  BOK    NM_005371.3  METTL1    NM_004528.2  MGST3 
NM_004332.1  BPHL    NM_017459.1  MFAP2    NM_022792.2  MMP19 
NM_007306.1  BRCA1   NM_145791.1  MGST1    NM_002448.1  MSX1 
NM_198590.1  BSG    NM_002413.3  MGST2    NM_005962.3  MXI1 
NM_001207.3  BTF3    NM_002414.3  CD99    NM_079424.1  MYL6 
NM_001731.1  BTG1    NM_002415.1  MIF    NM_032104.1  PPP1R12B 
NM_007311.2  BZRP    NM_022791.2  MMP19    NM_004547.4  NDUFB4 
NM_172369.1  C1QG    NM_002434.1  MPG    NM_182739.1  NDUFB6 
NM_001217.2  CA11    NM_021126.3  MPST    NM_005005.1  NDUFB9 
NM_000387.3  SLC25A20    NM_012331.2  MSRA    NM_020529.1  NFKBIA 
NM_006888.2  CALM1   NM_002451.3  MTAP    NM_002520.4  NPM1 
NM_005184.1  CALM3   NM_015675.1  GADD45B    NM_002607.2  PDGFA 
NM_005185.2  CALML3    NM_001002841.1  (MYL4    NM_005022.2  PFN1 
NM_001745.2  CAMLG   NM_079423.1  MYL6    NM_000942.4  PPIB 
NM_001003962.1  CAPNS1    NM_002478.3  MYOD1    NM_206873.1  PPP1CA 
NM_004346.2  CASP3    NM_032103.1  PPP1R12B   NM_183079.1  PRNP 
NM_001755.2  CBFB    NM_005594.2  NACA    NM_002765.2  PRPS2 
NM_004059.3  CCBL1    NM_182744.1  NBL1    NM_145888.1  KLK10 
NM_001759.2  CCND2   NM_014222.2  NDUFA8    NM_002790.2  PSMA5 
NM_199246.1  CCNG1   NM_004548.1  NDUFB10    NM_152255.1  PSMA7 
NM_001239.2  CCNH    NM_004549.3  NDUFC2    NM_176783.1  PSME1 
NM_001763.1  CD1A    NM_002496.1  NDUFS8    NM_183236.1  RAB27A 
NM_000733.2  CD3E    NM_181827.1  NF2    NM_004583.2  RAB5C 
NM_001769.2  CD9    NM_001001716.1  NFKBIB    NM_133629.1  RAD51L3 
NM_005191.2  CD80    NM_005008.2  NHP2L1    NM_021033.4  RAP2A 
NM_152942.1  TNFRSF8    NM_198175.1  NM23A/NME1    NM_002899.2  RBP1 
NM_001244.2  TNFSF8    NM_000904.1  NQO2    NM_000976.2  RPL12 
NM_001001392.1  CD44    NM_000270.1  NP    NM_001016.2  RPS12 
NM_198793.1  CD47    NM_199185.1  NPM1    NM_000331.2  SAA1 
NM_000560.2  CD53    NM_006172.1  NPPA    NM_005981.3  TSPAN31 
NM_203330.1  CD59    NM_002524.2  NRAS    NM_002970.1  SAT 
NM_004357.3  CD151    NM_004559.2  YBX1    NM_006745.2  SC4MOL 
NM_001786.2  CDC2    NM_007105.1  SLC22A18AS    NM_006746.3  SCML1 
NM_033534.1  CDC2L2    NM_005602.4  CLDN11    NM_001037.3  SCN1B 
NM_052827.1  CDK2    NM_175568.1  P2RX4    NM_003000.1  SDHB 
NM_000075.2  CDK4    NM_175081.1  P2RX5    NM_183352.1  SEC13L1 
NM_078467.1  CDKN1A    NM_002567.2  PBP    NM_014563.2  TRAPPC2 
NM_004064.2  CDKN1B    NM_002573.2  PAFAH1B3   NM_003016.2  SFRS2 
NM_000077.3  CDKN2A    NM_181696.1  PRDX1    NM_152235.1  SFRS8 
NM_078626.1  CDKN2C    NM_000281.2  TCF1/PCBD1    NM_004593.1  SFRS10 
NM_005195.2  CEBPD   NM_032403.1  PCDHGC3   NM_173217.1  ST6GAL1 
NM_001806.2  CEBPG   NM_002592.2  PCNA    NM_170679.1  SKP1A 
NM_001809.2  CENPA   NM_033023.1  PDGFA    NM_005984.1  SLC25A1 
NM_004365.2  CETN3    NM_002608.1  PDGFB    NM_022875.1  SMN2 
NM_005507.2  CFL1    NM_213612.1  SLC25A3    NM_004596.3  SNRPA 
NM_001817.1  CEACAM4    NM_002642.3  PIGC    NM_198216.1  SNRPB 
NM_152253.1   CHKB   NM_002648.2  PIM1    NM_198220.1  SNRPB2 
NM_013324.4  CISH    NM_006224.2  PITPNA    NM_177542.1  SNRPD2 
NM_001281.2  CKAP1    NM_002653.3  PITX1    NM_004175.3  SNRPD3 
NM_001284.2  AP3S1    NM_000929.1  PLA2G5    NM_022807.2  SNRPN 
NM_001288.4  CLIC1    NM_001005376.1  PLAUR    NM_000454.4  SOD1 
NM_001291.2   CLK2   NM_021910.1  FXYD3    NM_006943.2  SOX12 
NM_001293.1  CLNS1A    NM_021105.1  PLSCR1    NM_001047.1  SRD5A1 
(Continued)12
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S-Table-1. (Continued)
GenBank   Gene   GenBank   Gene   GenBank   Gene 
Accession No.   Symbol   Accession No.   Symbol   Accession No.   Symbol 
NM_007097.2  CLTB    NM_153321.1  PMP22    NM_003132.1  SRM 
NM_004368.2  CNN2    NM_174930.2  PMS2L5    NM_003135.1  SRP19 
NM_007310.1  COMT    NM_001003686.1   PMS2L3   NM_003144.2  SSR1 
NM_001300.3  KLF6    NM_022716.1  PRRX1    NM_003155.1  STC1 
NM_001861.2  OX4I1    NM_002696.1  POLR2G    NM_177528.1  SULT1A2 
NM_001305.3  CLDN4    NM_006232.2  POLR2H    NM_004177.3  STX3A 
NM_001306.2  CLDN3    NM_006233.4  POLR2I    NM_004604.3  STX4A 
NM_001307.3  CLDN7    NM_021129.2  PPA1    NM_003164.2  STX5A 
NM_001878.2  CRABP2   NM_203430.1  PPIA    NM_177534.1  SULT1A1 
NM_004379.2  CREB1    NM_000943.4  PPIC    NM_003166.2  SULT1A3 
NM_001310.2  CREBL2   NM_177951.1  PPM1A    NM_181491.1  SURF5 
NM_181571.1  CREM    NM_177969.1  PPM1B    NM_014231.3  VAMP1 
NM_005206.3  CRK    NM_206877.1  PPP1CB    NM_014232.1  VAMP2 
NM_005207.2  CRKL    NM_002710.1  PPP1CC    NM_005638.3  SYBL1 
NM_001889.2  CRYZ    NM_006241.3  PPP1R2    NM_006754.2  SYPL1 
NM_139014.1  MAPK14   NM_002715.1  PPP2CA    NM_003187.3  TAF9 
NM_177436.1  CSE1L    NM_178002.1   PR 53/PPP2R4   NM_005643.2  TAF11 
NM_022644.2  CSH2    NM_000945.3  PPP3R1    NM_172208.1  TAPBP 
NM_177560.2  CSNK2A1    NM_005399.3  PRKAB2    NM_134324.1  TARBP2 
NM_001320.5  CSNK2B   NM_207578.1  PRKACB    NM_201437.1  TCEA1 
NM_001321.1  CSRP2    NM_212461.1  PRKAG1    NM_213648.1  TCF7 
NM_000396.2  CTSK    NM_138981.1  MAPK10    NM_181738.1  PRDX2 
NM_004394.1  DAP    NM_002756.2  MAP2K3    NM_201443.1  TEAD4 
NM_020548.4  DBI    NM_002764.2  PRPS1    NM_003201.1  TFAM 
NM_001924.2  GADD45A    NM_139277.1  KLK7    NM_174886.1  TGIF 
NM_004083.4  DDIT3    NM_002774.2  KLK6    NM_003255.3  TIMP2 
NM_001355.2  DDT    NM_213633.1  PSG4    NM_003270.2  TSPAN6 
NM_030655.2  DDX11    NM_203287.1  PSG11    NM_003271.3  TSPAN4 
NM_213566.1  DFFA    NM_148976.1  PSMA1    NM_021137.3  TNFAIP1 
NM_000791.2  DHFR    NM_002789.3  PSMA4    NM_000363.3  TNNI3 
NM_007326.1  CYB5R3   NM_002791.1  PSMA6    NM_005079.1  TPD52 
NM_138281.1  DLX4    NM_002794.3  PSMB2    NM_003287.2  TPD52L1 
NM_203316.1  DPAGT1   NM_002801.2  PSMB10    NM_199362.1  TPD52L2 13
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